WO2010057804A1 - Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs - Google Patents

Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs Download PDF

Info

Publication number
WO2010057804A1
WO2010057804A1 PCT/EP2009/064839 EP2009064839W WO2010057804A1 WO 2010057804 A1 WO2010057804 A1 WO 2010057804A1 EP 2009064839 W EP2009064839 W EP 2009064839W WO 2010057804 A1 WO2010057804 A1 WO 2010057804A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
triglyceride
fatty acids
fat emulsion
pharmaceutical preparation
Prior art date
Application number
PCT/EP2009/064839
Other languages
German (de)
English (en)
Inventor
Michael Boll
Original Assignee
B. Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41581163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010057804(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0921917A priority Critical patent/BRPI0921917B8/pt
Priority to US13/126,245 priority patent/US20110207819A1/en
Priority to EP09760502.6A priority patent/EP2355813B1/fr
Priority to MX2011005201A priority patent/MX338223B/es
Priority to ES09760502.6T priority patent/ES2561207T3/es
Application filed by B. Braun Melsungen Ag filed Critical B. Braun Melsungen Ag
Priority to RU2011124887/15A priority patent/RU2528108C2/ru
Priority to CA2739390A priority patent/CA2739390C/fr
Priority to JP2011536823A priority patent/JP2012509292A/ja
Priority to CN200980145702.6A priority patent/CN102215839B/zh
Publication of WO2010057804A1 publication Critical patent/WO2010057804A1/fr
Priority to US14/930,723 priority patent/US20160051506A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of Critical Illness Polyneuropathy (CIP) and Critical Illness Myopathy (CIM). Furthermore, the invention relates to an isotonic fat emulsion comprising at least one triglyceride having at least one fatty acid residue with an odd number of carbon atoms, wherein the fatty acid residue has a carbon chain having 5 to 15 carbon atoms.
  • CIP Critical Illness Polyneuropathy
  • CCM Critical Illness Myopathy
  • the invention relates to the use of the isotonic fat emulsion as a dietetic and further the invention relates to the use of the pharmaceutical preparation / isotonic fat emulsion in parenteral nutrition or as part of a dietetic, in particular the use of a fat emulsion for the artificial nutrition of septic intensive care patients.
  • CIP Critical Illness Polyneuropathy
  • CIM Critical Illness Myopathy
  • Another background of the present invention is in the field of artificial nutrition of intensive care patients by fat emulsions for intravenous use or lipid-containing diets.
  • Fat emulsions for parenteral nutrition serve to deliver fats in an intravenously acceptable dosage form when normal oral nutrition is not possible or medically contraindicated.
  • Common fat emulsions in the art are made from vegetable oils such as safflower oil or soybean oil, in some cases additionally containing triglycerides of medium-long fatty acids (so-called medium-chain triglycerides (MCT)) and / or oils of marine origin (fish oils mostly from cold-water fish).
  • MCT medium-chain triglycerides
  • DE-OS 37 21 137 describes lipid emulsions for parenteral nutrition comprising eicosapentaenoic acid triglyceride and / or docosahexaenoic acid triglyceride, or fish oils containing such triglycerides, as well as vegetable oils containing omega-6 fatty acids and MCT.
  • EP 0 120 169 B1 discloses synthetic triglycerides which contain a polyunsaturated fatty acid (preferably eicosapentaenoic acid) at the central carbon atom of the glycerol molecule can carry.
  • the glycerides prepared according to this specification can be used for nutrition, nutritional supplementation or therapeutic nutritional medicines.
  • US-4,526,902 describes mixtures comprising 25-75% by weight of eicosapentaenoic acid and one omega-6 fatty acid, which are used enterally as a component of pharmaceuticals or fat-containing foods such as butter or the like.
  • US 2008/0132571 A1 discloses preparations and methods for the treatment of catabolism effects in patients, wherein odd-numbered fatty acids and their glycerides are used to increase the intracellular ratio of AMP to ATP and to increase the activity of the AMP-activated protein kinase (AMPK) to be brought.
  • AMPK AMP-activated protein kinase
  • the object of the present invention was to provide a pharmaceutical preparation for accompanying nutritive treatment critically ill, z. B. septic intensive care patients and for the prophylaxis and treatment of subsequent complications of intensive care such as CIP and / or CIM to provide.
  • An object of the present invention is thus a pharmaceutical preparation for the prophylaxis or treatment of CIP and / or CIM, comprising a fat emulsion with at least one triglyceride (A) of the formula (I),
  • radicals R 1 , R 2 or R 3 are independently of one another.
  • the triglyceride (A) of the fat emulsion to be used in the present invention consists of glycerol esterified with fatty acids, at least one of which has an odd number of carbon atoms of 5 to 15 carbon atoms.
  • the odd-numbered alkanoyles have a chain length of 5 to 15 carbon atoms. It is preferably the alkanoyle which is selected from one or more of the following fatty acids selected from the group consisting of pentanoic acid (C5: 0, n-valeric acid), heptanoic acid (C7: 0, enanthic acid), nonanoic acid (C9: 0, pelargonic acid) , Undecanoic acid (Cl 1: 0, undecylic acid), tridecanoic acid (C13: 0, tridecylic acid) and pentadecanoic acid (C 15: 0, pentadecylic acid) are derived.
  • pentanoic acid C5: 0, n-valeric acid
  • heptanoic acid C7: 0, enanthic acid
  • nonanoic acid C9: 0, pelargonic acid
  • Undecanoic acid Cl 1: 0, undecylic acid
  • tridecanoic acid C13
  • At least one of the radicals R, R 2 or R in the triglyceride (A) has a chain length of 5 to 9 carbon atoms.
  • At least one of the radicals R 1 , R 2 or R 3 in the triglyceride (A) -Heptanoyl ie a triglyceride consisting of an esterified glycerol, wherein at least one, preferably at least two hydroxyl groups Heptanoic acid are esterified.
  • triglyceride (A) is triheptanoin, a glycerin in which the three hydroxy groups are esterified with n-heptanoic acid.
  • the synthesis of the triglyceride (A) is familiar to the person skilled in the art.
  • the required odd-numbered fatty acids (pentane, heptane, nonane, undecane, tridecane and pentadecanoic) are commercially available, for example from Sigma Chemicals Co ..
  • triheptanoin can be obtained from Condea Chemie GmbH (Wirten, Germany) as special oil 107.
  • Trinonanoin, Triundecanoin or Tripentadecanoin are z. B. by Chemos GmbH (Regenstauf, Germany) available.
  • the triglyceride (A) may, in addition to the essential fatty acid radicals according to the invention having an odd number of carbon atoms between 5 and 15, also have further even-numbered fatty acid radicals.
  • fat emulsions are preferred which have the triglyceride (A) in which at least one fatty acid residue is derived from omega-3 and / or omega-6 fatty acids.
  • Omega-3 and omega-6 fatty acids are biologically important building blocks / nutrients that the human organism itself can not fully produce and that act as precursors to prostaglandins, eicosanoids and structural components of cell membranes.
  • omega-6 fatty acids are various oils of vegetable origin, including soybean oil and safflower diuretic oil, the use of which is prior art for the preparation of intravenous fat emulsions.
  • soybean oil oils of marine origin
  • omega-3 fatty acids in intravenous fat emulsions
  • EP-A-0298293 oils of marine origin
  • highly purified fish oil concentrates derived from cold-water fish such as salmon, herring, Sardines or mackerel
  • their content of omega-3 fatty acids is preferably 40% or more.
  • Myristic acid C14 0, palmitic acid C 16: 0, stearic acid C 18: 0), monounsaturated fatty acids (palmitoleic acid C16: l, oleic acid C18: l), polyunsaturated fatty acids of the omega-3 and omega-6 type, eg eicosapentaenoic acid ( EPA, C20: 5 omega-3), docosahexaenoic acid (DHA, C22: 6 omega-3), linoleic acid (LA, C18: 2 omega-6) or gamma-linolenic acid (GLA, C18: 3 omega-6).
  • the triglyceride (A) is present as a randomized structured lipid having a random distribution of the odd carbon number alkanoyl radicals and the alkanoyl radicals even carbon number at positions sn-1, sn-2 and sn-3 of the triglyceride molecule (A).
  • the triglyceride (A) is present as a chemically defined structured lipid, that is, it has a chemically defined distribution of the odd number carbon number alkanoyl residues in positions sn-1 and sn-3 and the alkanoyl residues even carbon number at position sn-2 of the triglyceride molecule.
  • the fat emulsions to be used according to the invention contain wholly or partially chemically defined or randomized structured lipids
  • vegetable oils are preferably used as the source of omega-6 fatty acids or fish oil as the source of omega-3 fatty acids for the preparation of the structured lipids.
  • Randomized structured triglycerides are obtainable, for example, by chemical transesterification of a mixture of a desired vegetable and / or fish oil with a triglyceride of odd-numbered fatty acids with a chain length of 5 to 15. In the case of chemically defined structured lipids, transesterification takes place enzymatically from the same basic materials.
  • the pharmaceutical preparation of the invention comprises a fat emulsion comprising at least one additional triglyceride (B) other than (A).
  • the triglyceride (B) comprises triglycerides of marine or plant origin. Since the recovery of pure omega-3 or omega-6 fatty acids from fish oil or vegetable oils or the chemical synthesis of these fatty acids on the one hand consuming and costly, while on the other hand, the said oils of marine or vegetable origin have a high content of the corresponding fatty acids, it is accordingly
  • the present invention does not require the isolation of omega-3 or omega-6 fatty acids or omega-3 or omega-6 fatty acids containing triglycerides from these oils, but the oils can be used as such for the preparation of the fat emulsions erf ⁇ ndungsloom to be used.
  • long-chain saturated fatty acids are automatically provided as their above-mentioned representatives myristic, palmitic and stearic, as well as the monounsaturated oleic acid, which is contained both in marine oils and - in a particularly high concentration - in olive oil.
  • Medium-chain fatty acids or triglycerides are contained in semi-synthetic MCT oil (miglyol oil) and more than 90% (based on the total fatty acid content) as caprylic and capric acid. In this form they are particularly suitable to be used as triglyceride (B) in the fat emulsion to be used according to the invention.
  • the amount of triglyceride (A) is from 50 to 80% by weight, more preferably from 60 to 70% by weight, based on the total weight of all triglycerides in the emulsion.
  • the pharmaceutical preparation according to the invention triglycerides in an amount of 5 to 30 wt.%, More preferably from 10 to 20 wt .-%, based on the total pharmaceutical preparation on.
  • the fat emulsion of the pharmaceutical preparation according to the invention contains, in addition to the triglyceride (A) and optionally other triglycerides / lipids, advantageously water for injection as well as other auxiliaries and additives corresponding to the prior art in the preparation of intravenous fat emulsions, e.g. Emulsifiers, co-emulsifiers, stabilizers and suitable substances for the adjustment of isotonicity.
  • triglyceride (A) and optionally other triglycerides / lipids advantageously water for injection as well as other auxiliaries and additives corresponding to the prior art in the preparation of intravenous fat emulsions, e.g. Emulsifiers, co-emulsifiers, stabilizers and suitable substances for the adjustment of isotonicity.
  • emulsifiers physiologically well-tolerated emulsifiers are used, such as.
  • the phospholipid content in the emulsion to be used according to the invention is preferably 0.4 to 2.0% by weight, preferably 0.6% to 1.5% by weight, in each case based on the total weight of the emulsion.
  • co-emulsifiers can be used, for.
  • the alkali salts of long chain fatty acids such as sodium stearate, sodium oleate, etc.
  • cholesterol or cholesterol esters eg, cholesterol acetate
  • their concentration as in the case of using cholesterol or cholesterol esters alone or in combination with other co-emulsifiers, is 0.01% by weight to 0.1% by weight, preferably 0.02% 0.04 wt .-%, each based on the total weight of the emulsion.
  • the fat emulsion of the pharmaceutical preparation according to the invention may be enriched with antioxidants which protect against the formation of undesired peroxides.
  • Suitable antioxidants are, in particular, vitamin E (alpha-, beta- or gamma-tocopherol) and vitamin C (for example as ascorbyl palmitate), vitamins E and C or their isomers or derivatives being present either alone or in combination can.
  • weight fraction is between 0.002 and 0.03% (alpha tocopherol) or 0.001 and 0.015% (ascorbyl palmitate), based in each case on the total weight of the emulsion to be used according to the invention.
  • the fat emulsion to be used according to the invention in the pharmaceutical preparation according to the invention also contains L-carnitine in an amount of preferably 0.01 to 0.1% by weight, in each case based on the total weight of the emulsion.
  • the preparation according to the invention may additionally contain the vitamins biotin and / or cobalamin: their concentrations are 1-10 mg biotin or 0.1-1 mg cobalamin per 100 g lipid content of the preparation.
  • the isotonization of the fat emulsion is preferably carried out with the aid of polyols such as glycerol, xylitol or sorbitol, which are used in an amount of preferably 2 to 3 wt .-% each based on the total weight of the emulsion.
  • the preferred isotonizing agent is glycerol.
  • the pharmaceutical agent according to the present invention is administered in a pharmaceutically effective amount.
  • the pharmaceutically effective dose i. the amount of triglyceride (A) to be supplied with the pharmaceutical preparation according to the invention to reduce the complications of severe, e.g. As septic diseases and their intensive care treatment to reduce their intensity and shorten duration, at 1 to 2 g per kg of body weight and day.
  • the supply preferably takes place continuously over 24 hours / day, but can also be divided into several portions, wherein an infusion rate of 0.25 g fat per kg body weight and hour should not be exceeded. In general, a multi-day medium to long-term administration is required to achieve the erfmdungswashe effect.
  • the application of the pharmaceutical preparation according to the invention is carried out as part of a completely parenteral or combined parenteral / enteral nutrition, as in seriously ill z.
  • the high energy content of the emulsion according to the invention should be taken into account in the total calorie intake with the parenteral or combined enteral / parenteral nutrition.
  • essential fatty acids omega-3 or omega-6
  • the latter need not be additionally substituted.
  • the particularly preferred presence of omega-3 fatty acid residues in the emulsion and their anti-inflammatory properties can be synergistic effects and additionally promote the healing process.
  • a further subject of the present invention is an isotonic fat emulsion comprising a triglyceride (A) of the formula (I)
  • R, R or R is an alkanoyl radical having an odd number of 5 to 15 carbon atoms and which comprises at least one additional triglyceride (B) other than (A) and having at least one fatty acid residue is selected from the group consisting of medium chain fatty acids comprising caprylic acid, capric acid or lauric acid; long-chain saturated fatty acids, including myristic acid, palmitic acid or stearic acid; monounsaturated fatty acids comprising palmitoleic or oleic acid; and omega-3 and omega-6 type polyunsaturated fatty acids comprising eicosapentaenoic acid, docosahexaenoic acid, linoleic acid and gamma-linolenic acid.
  • isotonic fat emulsion according to the invention correspond to the fat emulsion which is to be used according to the invention in the pharmaceutical preparation according to the invention.
  • Another object of the present invention is the use of the isotonic fat emulsion according to the invention as a dietetic.
  • the isotonic fat emulsion is preferably used for enteral nutrition.
  • Another object of the present invention is a dietetic, comprising at least one triglyceride (A) of the formula (I).
  • the dietetic preferably comprises the isotonic fat emulsion according to the invention.
  • Another object of the present invention is the use of the isotonic fat emulsion according to the invention or a fat emulsion with at least one triglyceride (A) of the formula (I) or the pharmaceutical preparation according to the invention for the artificial nutrition of septic intensive care patients and / or for parenteral nutrition.
  • a further object is a medicament comprising at least one triglyceride (A) of the formula (I),
  • the medicament preferably comprises the isotonic fat emulsion according to the invention.
  • the lipophilic components 1-9 listed in the table below are roughly mixed and dispersed with the aid of an Ultra-Turrax homogenizer. Thereafter, the hydrophilic components 10-13 are added using sodium oleate or stearate and NaOH as aqueous solutions and adjusting the pH of the batch mixture to 8.0-9.0 using the latter components. The actual homogenization of the batch is then carried out in a high-pressure homogenizer at pressures of about 400 kg / cm.
  • the finished emulsion is filled into suitable glass or plastic containers and heat sterilized according to the usual procedures for parenteralia. This results in a sterile, pyrogen-free and stable fat emulsion having an average droplet size of less than 0.5 microns and has a shelf life of at least 24 months at room temperature.
  • triglyceride (A) consisting of glycerin, which with heptanoic acid in the positions sn-1 and sn-3 and eicosapentaenoic acid: the at position sn-2 ((EPA), C2O 5 omega-3) Triglycerides esterified is used.

Abstract

La présente invention porte sur une préparation pharmaceutique pour la prophylaxie et le traitement de la polyneuropathie acquise en réanimation (Critical Illness Polyneuropathy, CIP) et de la myopathie acquise en réanimation (Critical Illness Myopathy, CIM). L'invention porte en outre sur une émulsion grasse isotonique comprenant au moins un triglycéride qui contient au moins un radical d'acide gras ayant un nombre impair d'atomes de carbone, le radical d'acide gras présentant une chaîne carbonée de 5 à 15 atomes de carbone.
PCT/EP2009/064839 2008-11-18 2009-11-09 Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs WO2010057804A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN200980145702.6A CN102215839B (zh) 2008-11-18 2009-11-09 用于人工喂养重病的重症特护患者的脂肪乳剂
US13/126,245 US20110207819A1 (en) 2008-11-18 2009-11-09 Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients
EP09760502.6A EP2355813B1 (fr) 2008-11-18 2009-11-09 Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs
MX2011005201A MX338223B (es) 2008-11-18 2009-11-09 Emulsion de grasas para alimentar artificialmente a pacientes seriamente enfermos en cuidados intensivos.
ES09760502.6T ES2561207T3 (es) 2008-11-18 2009-11-09 Emulsión grasa para alimentar artificialmente a pacientes gravemente enfermos de cuidados intensivos
BRPI0921917A BRPI0921917B8 (pt) 2008-11-18 2009-11-09 formulação farmacêutica.
RU2011124887/15A RU2528108C2 (ru) 2008-11-18 2009-11-09 Жировая эмульсия для искусственного питания тяжелобольных, нуждающихся в интенсивной терапии
CA2739390A CA2739390C (fr) 2008-11-18 2009-11-09 Emulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs
JP2011536823A JP2012509292A (ja) 2008-11-18 2009-11-09 重症の集中治療患者への人工栄養のための脂肪乳剤
US14/930,723 US20160051506A1 (en) 2008-11-18 2015-11-03 Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008057867A DE102008057867A1 (de) 2008-11-18 2008-11-18 Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
DE102008057867.3 2008-11-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/126,245 A-371-Of-International US20110207819A1 (en) 2008-11-18 2009-11-09 Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients
US14/930,723 Continuation US20160051506A1 (en) 2008-11-18 2015-11-03 Fat Emulsion for Artificially Feeding Seriously Ill Intensive Care Patients

Publications (1)

Publication Number Publication Date
WO2010057804A1 true WO2010057804A1 (fr) 2010-05-27

Family

ID=41581163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/064839 WO2010057804A1 (fr) 2008-11-18 2009-11-09 Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs

Country Status (12)

Country Link
US (2) US20110207819A1 (fr)
EP (1) EP2355813B1 (fr)
JP (1) JP2012509292A (fr)
KR (1) KR20110084513A (fr)
CN (1) CN102215839B (fr)
BR (1) BRPI0921917B8 (fr)
CA (1) CA2739390C (fr)
DE (1) DE102008057867A1 (fr)
ES (1) ES2561207T3 (fr)
MX (1) MX338223B (fr)
RU (1) RU2528108C2 (fr)
WO (1) WO2010057804A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US11406616B2 (en) 2016-06-08 2022-08-09 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
JP5009451B1 (ja) * 2011-01-31 2012-08-22 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
CN106900888B (zh) * 2015-12-23 2021-12-24 丰益(上海)生物技术研发中心有限公司 含有奇数碳脂肪酸结构脂的油脂组合物及其应用
CN109602704A (zh) * 2019-01-23 2019-04-12 广东嘉博制药有限公司 丁酸氯维地平脂肪乳注射液及其制备工艺
CN110326789A (zh) * 2019-06-11 2019-10-15 上海互众药业有限公司 一种脂肪乳食品补充液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162833A1 (en) * 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
WO2004103307A2 (fr) * 2003-05-20 2004-12-02 Baylor Research Institute Acides gras a cinq ou quinze carbones destines a traiter des troubles metaboliques et utilises comme complements nutritionnels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515174A1 (fr) 1981-10-23 1983-04-29 Roussel Uclaf Nouveaux triglycerides, procede de preparation et d'applications en dietetique et en therapeutique
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
DE3721137A1 (de) 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
DE3722540A1 (de) 1987-07-08 1989-01-19 Fresenius Ag Fettemulsion, verfahren zu ihrer herstellung und ihre verwendung
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
RU2155612C2 (ru) * 1997-01-30 2000-09-10 Скрипченко Наталия Викторовна Способ лечения острых инфекционных заболеваний периферической нервной системы
NZ513329A (en) * 1999-02-05 2003-11-28 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
BR0213183A (pt) * 2001-10-11 2004-08-31 Applied Research Systems Uso de ativadores gp130 em neuropatia diabética
WO2006014353A2 (fr) * 2004-07-02 2006-02-09 Baylor Research Institute Methode de traitement d'une maladie de surcharge due a l'accumulation de glycogenes ou de polysaccharides
ES2285584T3 (es) * 2005-02-16 2007-11-16 Dr. Straetmans Chemische Produktion Gmbh Formulaciones fotoprotectoras cosmeticas y dermatologicas con un contenido en filtros uva quimicos y triheptanonina.
NZ575655A (en) 2006-09-26 2012-06-29 Baylor Res Inst Nutrient sensor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US20030162833A1 (en) * 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
WO2004103307A2 (fr) * 2003-05-20 2004-12-02 Baylor Research Institute Acides gras a cinq ou quinze carbones destines a traiter des troubles metaboliques et utilises comme complements nutritionnels

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AI-NASIRY S; GEUSENS N; HANSSENS M; LUYTEN C; PIJNENBORG R.: "The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells", HUMAN REPRODUCTION, vol. 22, no. 5, 2007, pages 1304 - 1309
HAMID R; ROTSHTEYN Y; RABADI L; PARIKH R; BULLOCK P.: "Comparison of alamarBlue and MTT assays for high through-put screening", TOXICOL IN VITRO, vol. 18, 2004, pages 703 - 10
NOCIARI MM; SHALEV A; BENIAS P; RUSSO C.: "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity", J IMMUNOL METH., vol. 213, 1998, pages 157 - 167
ROE C R ET AL: "Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 110, no. 2, 1 July 2002 (2002-07-01), pages 259 - 269, XP002995380, ISSN: 0021-9738 *
SYKES ML; AVERY VM.: "Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427", AM J TROP MED HYG., vol. 81, no. 4, 2009, pages 665 - 74
VAN DER HARST MR; BULL S; LAFFONT CM; KLEIN WR.: "Gentamicin neprotoxicyty-a comparison of in vitro finding with in vivo experiments in equines", VET RES COMMUN., vol. 29, no. 3, 2005, pages 247 - 61

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8545896B2 (en) 2011-09-29 2013-10-01 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US11406616B2 (en) 2016-06-08 2022-08-09 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Also Published As

Publication number Publication date
CA2739390C (fr) 2016-05-03
DE102008057867A1 (de) 2010-05-20
BRPI0921917B1 (pt) 2020-08-25
BRPI0921917B8 (pt) 2021-05-25
EP2355813A1 (fr) 2011-08-17
RU2528108C2 (ru) 2014-09-10
ES2561207T3 (es) 2016-02-25
BRPI0921917A2 (pt) 2015-12-29
RU2011124887A (ru) 2012-12-27
CA2739390A1 (fr) 2010-05-27
KR20110084513A (ko) 2011-07-25
CN102215839A (zh) 2011-10-12
MX338223B (es) 2016-04-08
US20110207819A1 (en) 2011-08-25
EP2355813B1 (fr) 2015-11-04
CN102215839B (zh) 2016-08-24
JP2012509292A (ja) 2012-04-19
MX2011005201A (es) 2011-06-01
US20160051506A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
EP2355813B1 (fr) Émulsion grasse pour l'alimentation artificielle de patients gravement malades en soins intensifs
EP0607231B1 (fr) Utilisation d'une emulsion afin de preparer un medicament administre par voie intra-veineuse pour taiter des maladies de la peau
DE60129134T2 (de) O/w emulsion
EP0456670B1 (fr) EMULSION GRASSE CONTENANT DES $g(v)-3-ACIDES GRAS POUR APPLICATION INTRAPERITONEALE, SA FABRICATION ET SON UTILISATION
DE69823548T2 (de) Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
DE69818704T2 (de) Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden
AT398779B (de) Fettsäurezusammensetzung, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung, die sie enthält
DE60116625T2 (de) Therapeutische kombinationen von fettsäuren
EP1633325B1 (fr) Emulsion d'huile pour la substitution hormonale postnatale
EP0637957B1 (fr) Utilisation d'une emulsion contenant des acides gras omega-3 pour la fabrication d'un medicament administrable par voie parenterale, pour le traitement de maladies inflammatoires
DE69625616T3 (de) Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
EP1799204A1 (fr) Compositions contenant des acides gras omega-3 et omega-6
EP0148303B1 (fr) Composition diététique
WO2016169941A1 (fr) Capsule de gel contenant du stérol et un agent de solubilisation
WO2000040236A1 (fr) Emulsion sterile et stable contenant des taxanes et son procede de production
EP0456764A1 (fr) Emulsion grasse pour application endotracheale, sa fabrication et son utilisation.
DE102009003980A1 (de) Propofol in triheptanoinhaltiger Trägeremulsion
DE60124516T3 (de) Kombination des lezithins mit ascorbinsäure
EP0651995A1 (fr) Emulsion H/E contenant de la cyclosporine pour administration orale
WO2000016770A1 (fr) Preparation pharmaceutique contenant du taxane et procede de preparation d'une telle composition
EP1147769A2 (fr) Utilisation d'acides gras polyinsaturés, en particulier des acides gras oméga 3, pour le traitement de l'énurésie et de l'incontinence

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980145702.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09760502

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2739390

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2524/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13126245

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20117010418

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005201

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011536823

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009760502

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011124887

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0921917

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110511